The European Commission and the World Health Organization (WHO) co-hosted a Global Vaccination Summit on 12 September to reverse the spread of vaccine-preventable diseases and stop the spread of vaccine misinformation. The discussions are summarised in the following actions and lessons.
These Guidelines, prepared by the Scientific Committee on Health, Environmental and Emerging Risks (SCHEER), concern guidance on how to perform benefit-risk assessment of phthalates used in certain medical devices.
The SCHEER was requested by DG ENV to peer review and validate the outcomes of a pilot on the foresight system for the systematic identification of emerging environmental issues in the field of new technologies in the urban environment. A summary of the SCHEER opinion was published as part of the report “FORENV: PILOT ON NEW TECHNOLOGIES IN THE URBAN ENVIRONMENT”.
The Conference will highlight the results of the current and previous EU Health Programmes and present the new approach in the future Multiannual Financial Framework for 2021-2027. Registration is open. The Conference will be broadcast live the day of the Conference via webstreaming.
The European Commission selected the shortlisted initiatives of the 2019 EU Health Award for cities, NGOs and schools seeking to prevent and reduce obesity in children and young people (6-18 years old).
In this last newsletter before the summer holiday, European Commission Director of Public Health John F. Ryan briefly discusses how summer impacts public health and the EU measures that keep EU citizens safe, not only during summer holidays, but all year round.
The recognition today by the U.S. Food and Drug Administration (FDA) of Slovakia, the last outstanding EU Member State, marks the full implementation of the EU-U.S. Mutual Recognition Agreement (MRA) for inspections of manufacturing sites for human medicines in their respective territories.
The editorial articles for this issue were prepared by the European Commission Directorate General for the Internal Market, Industry, Entrepreneurship and SMES (DG GROW).
In a joint letter published today, the European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) reminded all sponsors of clinical trials conducted in the European Union of their obligation to make summaries of results of concluded trials publicly available in the EU Clinical Trials Database.
The US Food and Drug Administration (FDA) confirmed the capability of Germany to carry out good manufacturing practice (GMP) inspections at a level equivalent to that of the US. There are now a total of 27 Member States whose inspection results the FDA can rely on to replace their own inspections.